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Abstract
Background: Lead-212 (212Pb, t1/2 = 10.6 h) and lead-203 (
203Pb, t1/2 = 51.9 h) are an
element-equivalent, or a matched theranostic radioisotope pair that show great potential
for application in targeted radionuclide therapy (TRT) and single-photon emission
computed tomography (SPECT), respectively. At TRIUMF we have produced both 203Pb
and 212Pb using TRIUMF’s TR13 (13MeV) and 500MeV cyclotrons, and subsequently
purified and evaluated both radioisotopes using a series of pyridine-modified DOTA
analogues in comparison to the commercially available chelates DOTA (1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid) and TCMC (1,4,7,10-tetraaza-1,4,7,10-
tetra(2-carbamoylmethyl)cyclododecane).
Results: Proton irradiation (12.8 MeV) of natural and enriched thallium-203 (203Tl) targets
gave 203Pb saturation yields of 134 ± 25 and 483 ± 3MBq/μA, respectively. Thorium-228
(228Th, t1/2 = 1.9 y), a by-product of
232Th proton spallation on TRIUMF’s main 500MeV
beamline (beamline 1A, BL1A), was recovered to build a 228Th/212Pb generator with the
ability to deliver up to 9–10MBq of 212Pb daily. Both lead isotopes were purified via solid
phase extraction chromatography (Pb resin), and isolated in an acetate form
([203/212Pb]Pb(OAc)2) suitable for direct radiolabeling of chelators and bioconjugates. A
series of cyclen-based chelators (herein referred to as DOTA-1Py, -2Py, and -3Py) along
with established chelates DOTA and TCMC were evaluated for their ability to
complex both 203Pb and 212Pb. All chelates incorporated 212Pb/203Pb efficiently,
with higher radiolabeling yields observed for the 212Pb-complexes.
Conclusion: The production of 203Pb and 212Pb was established using TRIUMF 13
MeV and 500 MeV cyclotrons, respectively. Both production methods provided
radiometals suitable for subsequent radiolabeling reactions using known and
novel chelates. Furthermore, the novel chelate DOTA-3Py may be a good candidate for
biomolecule conjugation and further theranostic 212Pb/203Pb studies.
Keywords: Lead-212, Lead-203, Thorium-228 generator, Thallium-203, Theranostic,
Cyclen, DOTA, Pyridyl, Chelators, Radiolabeling
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Background
The fields of molecular imaging (MI) and targeted radionuclide therapy (TRT) rely on
incorporating radioisotopes onto biomolecules that show high affinity for cancer cells
in order to impart diagnostic and/or therapeutic information to health researchers and
clinicians. Advances in understanding the molecular processes that define normal and
aberrant cell behavior has led to the identification of an increasing number of biomo-
lecular targets that can be exploited for targeted delivery of imaging and therapeutic
agents specific to diseased cells. With targeted compound delivery, one can minimize
ambiguous diagnostic outcomes and/or undesirable side effects during treatment by
avoiding uptake or damage induced by off-target radiopharmaceutical accumulation
(Kumar Bharti et al. 2012; Bono et al. 2003). MI relies on radionuclides which emit
photons, either directly (such as in electron capture [EC] decay) or indirectly (such as
in positron [β+] decay), while nuclides that emit cytocidal particles (such as beta [β−],
alpha [α] particles, or Meitner-Auger electrons) can be used for TRT. Theranostic ra-
diopharmaceuticals represent a combination of both MI and TRT isotopes onto a com-
mon biomolecule that can be used to both image and then treat disease, leading to a
potent compound pairing that allows for visualization of the molecular processes
underpinning disease and verifies cellular target presence for subsequent therapy (Yor-
danova et al. 2017; Rösch et al. 2017).
In general, a theranostic pair of radionuclides comprise of two chemically similar iso-
topes, one which can be used for imaging, and the other for therapy (Elgqvist et al.
2014). When the theranostic pair is composed of radionuclides of two different ele-
ments, the biodistribution of the radiopharmaceutical may differ and thus any quantita-
tive dosimetric information predicted from the diagnostic imaging results may not be
reflective of the therapeutic agent; this discrepancy can be minimized with matched
theranostic pairs (Elgqvist et al. 2014). Matched theranostic pairs utilize different iso-
topes of the same element for diagnosis and therapy, giving rise to identical chemical
species and thus biodistribution, which can give further insight on the suitability of the
radiopharmaceutical for a patient being assessed or treated (Yordanova et al. 2017).
Only the different half lives and their effect on biodistribution may need to be
considered.
Lead-203 (203Pb, t1/2 = 51.9 h) and lead-212 (
212Pb, t1/2 = 10.6 h) are an element-
equivalent matched theranostic pair that have generated significant interest for use in
theranostic radiopharmaceutical development (Máthé et al. 2016). 212Pb emits two β−
particles and one α particle during its decay chain and can be used for therapy. 203Pb
decays by electron capture to ground state thallium-203 (203Tl), followed by the emis-
sion of a gamma-photon (279 keV; 81%) that is compatible for single photon emission
computed tomography (SPECT) imaging while the lack of radioactive daughter prod-
ucts simplifies dosimetry calculations (Horlock et al. 1975).
212Pb is a member of the uranium-232 (232U) and thorium-232 (232Th) decay chain,
and is commonly produced by the decay of 228Th (t1/2 = 1.9 y) (Hassfjell 2001; Hassfjell
and Hoff 1994; Zucchini and Friedman 1982) and radium-224 (224Ra, t1/2 = 3.64 days)
(Mirzadeh 1998; Westrøm et al. 2017; Atcher et al. 1988; Bartoś et al. 2013; Milenic
et al. 2015; Baidoo et al. 2013; Li et al. 2017) (Fig. 1). Many 228Th generators exploit
the chemical or physical separation of the daughters 224Ra (Zucchini and Friedman
1982) and radon-220 (220Rn, t1/2 = 55.6 s) (Hassfjell 2001; Hassfjell and Hoff 1994) by
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using cation exchange columns (Zucchini and Friedman 1982) or chamber walls
(Hassfjell and Hoff 1994), and glass bubblers (Hassfjell 2001), respectively. 212Pb has
been collected using nitric (Hassfjell 2001) or hydrochloric (Zucchini and Friedman
1982) acid or water (Hassfjell and Hoff 1994) to give yields of 85–90%. However, many
of the 228Th generators reported to date have difficulty providing practical quantities of
212Pb due to the radiolytic damage to the generator matrix material when higher levels
of activity are included. To circumvent this, 224Ra generators have been used to pro-
duce 212Pb by separating 224Ra from 228Th on an anion exchange resin (Bartoś et al.
2013), followed by loading onto a cation (Mirzadeh 1998; Atcher et al. 1988; Bartoś
et al. 2013; Milenic et al. 2015; Baidoo et al. 2013) exchange resin, actinide resin
(Westrøm et al. 2017), or Pb-selective extraction resin (Li et al. 2017), from which
212Pb is eluted using HCl (Mirzadeh 1998; Westrøm et al. 2017; Atcher et al. 1988;
Bartoś et al. 2013; Milenic et al. 2015; Baidoo et al. 2013) or a complexing agent (Li
et al. 2017).
203Pb is a cyclotron produced isotope and can be prepared from charged particle
(proton, deuteron, and alpha particle) bombardment of thallium (natural abundance
29.5% 203Tl, 70.5% 205Tl) (Horlock et al. 1975). At the end of bombardment, the thallium
targets are dissolved in nitric acid (Horlock et al. 1975; Li et al. 2017; Henriksen and Hoff
1998; Garmestani et al. 2005) or a mix of nitric and hydrochloric acid (Máthé et al. 2016),
before loading onto a Pb-selective extraction resin (Li et al. 2017; Henriksen and Hoff
1998; Garmestani et al. 2005), or anion exchange resin (Máthé et al. 2016). Alternatively,
203Pb is co-precipitated with Fe (OH)3 (Horlock et al. 1975) and eluted using complexing
agents (Henriksen and Hoff 1998), dilute nitric acid (Li et al. 2017; Garmestani et al.
2005), or hydrochloric acid (Máthé et al. 2016). Many of the purification methods for both
212Pb and 203Pb produce large eluant volumes, of which the composition may be incom-
patible with radiolabeling, thus requiring evaporation and redissolution steps which can
result in further reduction of yield or introduction of interfering stable impurities.
In this study, extraction chromatography and small volumes of radiolabeling-
compatible complexing agents are used to elute cyclotron produced 203Pb and 228Th-
generator produced 212Pb to shorten processing time and allow direct radiolabeling of
the purified 203/212Pb isotopes. A novel 228Th/212Pb generator concept was applied
using a 228Th generator stock solution obtained via 232Th spallation on TRIUMF’s 500
MeV cyclotron. The preparation of the 228Th stock allowed direct loading onto Pb-
selective resin, which returned 228Th directly to a storage vessel followed by elution of
absorbed 212Pb with ammonium acetate (NH4OAc). We present the production of the
203Pb and 212Pb theranostic pair using TRIUMF’s TR13 (13MeV) and 500MeV cyclo-
tron, subsequent radiochemical purification and isotope characterization. The separated
Fig. 1 Decay scheme of 228Th to 212Pb and stable 208Pb
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radioisotopes were evaluated alongside each other for radiolabeling a series of TRIUMF
developed, pyridine based-DOTA analogues (Yang et al. 2021) along with commercial




All solvents and reagents were purchased from commercial suppliers (Sigma Aldrich,
Fisher Scientific, VWR) and used as received, unless otherwise noted. Ultrapure nitric
acid (Environmental Grade) was purchased from VWR and Ultrapure HCl (TraceSE-
LECT), NaOH (99.99% trace metal grade), and ammonium acetate (ACS grade) were
purchased from Fisher Scientific. Pb resin (Di-t-butylcyclohexano 18-crown-6, 100–
150 μm particle size) was purchased from Eichrom Technologies (Lisle, IL). 1 mL poly-
propylene cartridges and 1/8″ polyethylene frits were purchased from United Chemical
Technologies (Lewistown, PA). Natural Tl (99.99% metals basis) was purchased from
Alfa Aesar (Tewksbury, MA) and enriched Tl (98.57 ± 0.05% 203Tl, 1.43 ± 0.05% 205Tl)
was purchased from BWX Technologies (Vancouver, BC). Human serum and Dowex
1 × 8 chloride form anion exchange resin (100–200 mesh) was purchased from Sigma
Aldrich (St. Louis, MO). DOTA and p-SCN-Bn-TCMC (referred to herein as TCMC)
were purchased from Macrocyclics (Plano, TX). DOTA-1Py (2,2′,2″-(10-(pyridin-2-
ylmethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl) triacetic acid), DOTA-2Py, (2,2′-
Fig. 2 Chemical structures of commercially available Pb-chelators DOTA, p-SCN-Bn-TCMC, and pyridine-
based cyclen analogues DOTA-1Py, DOTA-2Py, DOTA-3Py radiolabeled herein
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(7,10-bis (pyridin-2-ylmethyl)-1,4,7,10-tetraazacyclododecane-1,4-diyl) diacetic acid) and
DOTA-3Py (2-(4,7,10-tris (pyridin-2-ylmethyl)-1,4,7,10-tetraazacyclododecan-1-yl) acetic
acid) were synthesized as previously described (Yang et al. 2021). Instant thin layer chro-
matography paper impregnated with silicic acid (iTLC-SA) was purchased from Agilent
Technologies (Santa Clara, CA). Deionized water was prepared on site using a Millipore
Direct-Q® 3UV water purification system. Nuclear magnetic resonance (NMR) spectra
were obtained using MeOD, DMSO-d6, or D2O. Signals were measured relative to the sig-
nal of the solvent. NMR spectra were obtained using a Bruker 400 (400MHz), Bruker 500
(500MHz), or a Bruker 600 (600MHz). Mass spectrometry was performed on an Agilent
6210 time-of-flight LC-MS spectrometer or an Advion expression LC-MS equipped with
an electrospray source. All radioactivity measurements for the 203Pb purification from Tl
targets and the 228Th/212Pb generator were performed using gamma ray spectroscopy on
an N-type co-axial high purity germanium (HPGe) gamma spectrometer (Canberra Indus-
tries) calibrated with a 20mL 152Eu and 133Ba source. Aliquots (5–100 μL) were removed
and diluted to the 20mL standard volume for measurement at a distance of at least 15 cm
from the detector until the peak area uncertainties were below 5%; dead time was kept
below 4%. Spectra were analyzed using the Genie 2000 software package (Version X,
Canberra Industries) using the 279 keV and 401 keV gamma lines for 203Pb measurement,
and 238 keV and 300 keV gamma lines for 212Pb measurement. To determine chemical
purity of the 203Pb and 212Pb elutes, 1–1.5mL aliquots were removed and analyzed by in-
ductively coupled plasma mass spectrometry (ICP-MS) at Chalk River Laboratories. The
High-Performance Liquid Chromatography (HPLC) system used for the analysis of 203Pb-
labeled chelators consisted of an Agilent 1260 Infinity II Quaternary Pump, Agilent 1260
autosampler, Raytest Gabi Star NaI (Tl) radiation detector, Agilent 1260 variable wave-
length detector, and Agilent 1260 analytical scale fraction collector with a Phenomenex
Luna 5 μm C18 100 Å liquid chromatography analytical (250 × 4.6mm – for serum stabil-
ity studies, 100 × 4.6mm – for radiolabeling) column. RadioTLC was performed using a
BioScan System 200 Image Scanner.
Production and purification of 228Th nitrate
228Th is a by-product of the 232Th proton spallation used to produce 225Ac on TRIUMF’s
main 500MeV cyclotron (Robertson et al. 2018; Robertson et al. 2017; Robertson et al.
2020). 228Th is isolated from other elements during bulk thorium precipitation, as previ-
ously described (Robertson et al. 2020). To produce the 228Th generator stock solution,
approximately 8 g of the ThCl4 salt was dissolved in 10M HCl (200mL) and loaded, via a
peristaltic pump at 2mL/min, onto a 10mL Dowex 1 × 8 chloride form anion exchange
resin column prepared as a slurry pre-conditioned with 10M HCl (40mL) prior to use.
The column was washed with 10M HCl (60mL); 228Th did not adsorb to the column and
thus was found in the load and wash fractions. Impurities were eluted from the column
using 1M HCl. The load and wash fractions were evaporated to dryness and exchanged
three times with 10M nitric acid before re-dissolving in 1M HNO3 (40mL) to produce
the generator stock solution and the radionuclidic purity was assessed by gamma spec-
troscopy. All fractions were counted immediately after collection and were counted once
again after 2 weeks to allow for the grow in of progeny (224Ra and 212Pb), which acted as a
surrogate for measuring 228Th in gamma spectroscopy.
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The 228Th/212Pb generator principle
The multi-component generator consists of: A peristaltic pump (Fig. 3a), running at 2
mL/min, to pump the 228Th generator stock solution (Fig. 3b) through an 80mg Pb
resin column (Fig. 3c), housed in a 1 mL polypropylene cartridge and preconditioned
with MilliQ water (5 mL) followed by 1M HNO3 (5 mL). The
228Th, 224Ra, and 212Bi
are not retained on the column and are returned to the stock bottle via the pump using
air to push the solution into a 50mL storage loop. A syringe attached to a female luer
fitting (Fig. 3d) was used to pass 1M HNO3 (5 mL) through the Pb resin column to
wash the column before eluting 212Pb with 1M NH4OAc (pH 7) into a collection vial
(Fig. 3e).
Tl target production
A 1.6 mm thick, 35 mm diameter aluminum plate (6082 alloy) with a centered 10mm
diameter indent (0.25–0.30 mm depth) was used as a backing plate to hold the Tl.
Fig. 3 Schematic of the 228Th/212Pb generator. a Peristaltic pump. b Generator stock solution in lead
shielded storage loop. c Pb resin column. d Syringe attached to a female luer fitting to control elution. e
Collection vial for 212Pb(OAc)2. Image created with BioRender.com
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Natural or enriched 203Tl (320–330mg) was pressed with a hydraulic press (Desktop
Pellet Press, Across International, 4 MPa) into a 10mm diameter pellet using a 10mm
die set and pressed into the aluminum backing indent (6MPa). The target was then
heated to 400 °C using a hotplate in a fume hood to allow for melting. Discolouration,
indicative of thallium oxide formation was observed on the pellet surface. After cooling,
the resultant thallium oxide was rinsed off the surface with deionized water. The struc-
tural integrity of the Al-Tl target was evaluated by scratch and drop testing from a
height of 1.5 m onto a hard surface. The target was inspected for signs of physical dam-
age before being vacuum sealed in a plastic envelope until irradiation.
Target irradiation
The Tl target plate was installed in a solid target holder (Zeisler et al. 2019) and 203Pb
produced via the 203Tl (p,n) 203Pb nuclear reaction using TRIUMF’s TR13 cyclotron
(Laxdal et al. 1994). The cross section of this reaction has a threshold energy of 8MeV
and a peak at 26.5MeV (Azzam et al. 2014), making a small energy cyclotron suitable
for production. The target plate was cooled via water (back) and helium (front) during
irradiation. The 13MeV protons were degraded to ~ 12.8MeV using a 25 μm thick
aluminum foil which separated the target system from the cyclotron vacuum. The
backing plate thickness was chosen to completely stop the proton beam. Irradiation
was performed at 8–9 μA for 2–4 h. After irradiation, the target was left in the target
holder for 18–24 h to allow short-lived radionuclides produced during the irradiation
[202mPb (t1/2 = 3.62 h)] to decay, reducing radiation exposure to personnel.
Purification of 203Pb
The target was dissolved in a beaker with 2M HNO3 (20 mL) on a 125 °C hot plate
after which the solution was allowed to cool to ambient temperature over 1–1.5 h. A 1
mL polypropylene cartridge was packed with Pb resin (60 mg) and was conditioned
with MilliQ water (5 mL) followed by 2M HNO3 (5 mL). The dissolved target solution
was loaded onto the column by gravity and washed with 2M HNO3 (5 mL) to remove
any residual thallium. The 203Pb was eluted with 1M NH4OAc (pH 7, 3 mL) at 0.5 mL/
min. The yield and radionuclidic purity of 203Pb in the load, wash, and elute fractions
were assessed using gamma spectroscopy. Chemical purity of the 203Pb elute was
assessed using ICP-MS to identify any stable metal species that may compete with Pb
during radiolabeling reactions.
Inductively coupled plasma mass spectrometry
Aliquots (1.5 mL; n = 3) of the 212Pb and 203Pb elutes were lyophilized to dryness and
diluted to 10mL using trace metal grade 1M HNO3. The analysis utilized a multi-
element standard1 for the measurement of common stable impurities which may inter-
fere with radiolabeling. Stable impurities found in blank samples, which contained 10
mL of trace metal grade 1M HNO3, were subtracted from the amount found in the
elutes to quantify the impurities in the elutes.
1Na, Mg, Al, Ca, Ti, V, Cr, Mn, Fe, Ni, Co, Cu, Zn, Ga, Ge, As, Se, Rb, Sr, Zr, Nb, Mo, Ru, Rh, Pd, Ag, Cd,
Sn, Te, Cs, Ba, La, Ce, Pr, Nd, Sm, Eu, Gd, Dy, Ho, Er, Tm, Yb, Lu, Hf, Ta, W, Re, Os, Ir, Pt, Au, Tl, Pb, Th,
Hg
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Non-radioactive Pb(II) complexes
Chelates (DOTA-xPy, x = 1–3) were screened for their ability to complex non-
radioactive Pb(II), with metal complex formation confirmed and characterized using
ESI-MS and 1H NMR. Briefly, Pb(OAc)2 (1.2 equiv., 5–6 μL of 7.8 mg/mL in H2O), was
added to 10–15mg of the respective chelator (1 equiv., DOTA-1Py, DOTA-2Py,
DOTA-3Py), and the pH adjusted to approximately pH 6 using HCl or NaOH. The re-
action mixture was stirred up to 2 h at ambient temperature, after which the solvent
was evaporated in vacuo to give a white solid. [Pb(DOTA-1Py)]− ESI−-MS: m/z found
642.1, calcd C20H28N5O6Pb (M
−) 642.18. [Pb(DOTA-2Py)] ESI+-MS: m/z found 677.1,
calcd C24H33N6O4Pb (M +H
+) 677.23. [Pb(DOTA-3Py)]+ ESI+-MS: m/z found 710.3,
calculated C28H36N7O2Pb (M
+) 710.27. 1H NMR spectra of the Pb-complexes can be
found in the Supporting Information.
212Pb and 203Pb radiolabeling studies
Chelators DOTA, TCMC, DOTA-1Py, DOTA-2Py, and DOTA-3Py were dissolved to
give stock solutions (10− 3 M) in deionized water. Serial dilutions were used to prepare
chelator solutions at 10− 4, 10− 5, and 10− 6 M in deionized water. A 10 μL aliquot of
each chelator (or water as a negative control) was diluted with 1M NH4OAc (pH 7,
80 μL). For 203Pb labeling studies, [203Pb]Pb(OAc)2 (50 kBq, 10 μL) was added and
mixed to begin the radiolabeling reaction at ambient temperature. For 212Pb labeling
studies, [212Pb]Pb(OAc)2 (23 kBq, 10 μL) was added to each reaction, all performed in
triplicate. The iTLC plate system used for both 203Pb and 212Pb studies was iTLC-SA
plates (2 cm × 10 cm, baseline at 1.5 cm) developed using EDTA (50 mM, pH 5.0).
Under these conditions, the labeled Pb remained at the baseline (Rf = 0) and free
203Pb2+ and 212Pb2+ migrated with the solvent front (Rf ~ 1). Aliquots (10 μL) were re-
moved from each reaction solution at 5, 30, and 60 min and analyzed via iTLC. For
212Pb, the plates were measured 24 h later to allow for the decay of free short-lived
daughter products (212Bi, t1/2 = 60.55 min).
203Pb-complex formation with the DOTA-
xPy ligands was further confirmed via analytical RP-HPLC (gradient: A, 0.1% TFA in
water; B, 0.1% TFA in acetonitrile; 0–100% B over 20 min, 1 mL/min) by co-injection of
pre-formed ‘stable’ Pb-complexes with the [203Pb]Pb-tracers and tracking both the UV
and radioactive chromatograms (Figure S16).
Human serum stability studies
To prepare the 203Pb labeled complexes for human serum stability studies, an aliquot
(10 μL) of the 10− 3 M chelator solution (or water as a negative control) was added to 1
M NH4OAc (pH 7, 80 μL) and [
203Pb]Pb(OAc)2 (100–125 kBq, 10 μL) and the reaction
was allowed to proceed for 1 h at ambient temperature. Prior to the start of the study,
an aliquot (10 μL) was removed and analyzed via iTLC-SA and developed as per the
method described in section above, to ensure quantitative radiolabeling. Human serum
(100 μL) was added and mixed and the reactions were incubated at 37 °C for 72 h post
serum addition. At 8, 24, 48, and 72 h time points, an aliquot (10 μL) of the reaction
mixture was removed and spotted on iTLC-SA plates and developed. At 72 h, the tubes
were removed from the incubator and acetonitrile (160 μL) was added to precipitate
the serum proteins. The tubes were centrifuged at 14,000 rpm for 20 min and then the
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supernatant was removed. The supernatant was diluted with deionized water (1.3 mL)
and analyzed using analytical Radio-RP-HPLC (gradient: A, 0.1% TFA in water; B, 0.1%
TFA in acetonitrile; 0–100% B over 30 min, 1 mL/min). To determine the % stability of
each lead complex, the area under the curves in the radioactivity trace was calculated.
The retention time of unbound “free” Pb2+ was 4.3 min, [203Pb][Pb(DOTA)]2− was 7.9
min, [203Pb][Pb(TCMC)]2+ was 9.3 min, [203Pb][Pb(DOTA-1Py)]+ was 8.6 min,
[203Pb][Pb(DOTA-2Py)] was 9.9 min, and [203Pb][Pb(DOTA-3Py)]− was 11.2 min.
Results
Isotope production
Initial isotopes present in the thorium precipitate included 228Th, 227Th (t1/2 = 18.7 d),
75Se (t1/2 = 119.8 d),
110mAg (t1/2 = 249.8 d),
103Ru (t1/2 = 39.2 d),
207Bi (t1/2 = 31.6 y),
88Zr (t1/2 = 83.4 d),
95Zr (t1/2 = 64.0 d),
95Nb (t1/2 = 35.0 d),
233Pa (t1/2 = 26.9 d),
121mTe
(t1/2 = 19.1 d),
121Te (t1/2 = 164.2 d),
124Sb (t1/2 = 60.2 d), and
125Sb (t1/2 = 2.8 y) (Fig. 4).
Further information on the activity of each isotope can be found in Table S3. 95Nb and
95Zr were removed via anion exchange, giving load and wash fractions for the generator
stock solution containing 75Se,110mAg, 103Ru, 207Bi, and 227Th, in addition to 228Th.
The purification of 212Pb from its parent isotope 228Th with a generator based on Pb-
selective extraction resin produced product with > 99% radiochemical purity (Figure
S1) with an average yield of 69.3 ± 4.4%. The initial radionuclide generator solution,
which initially contained 9.780 ± 0.002MBq of 228Th, was used to supply 212Pb for at
least 2 years. The average elution profile is shown in Fig. 5.
Radiochemically-pure 203Pb was produced and isolated from irradiated aluminum-
backed thallium targets (Figure S2) with an average yield, decay corrected to the end of
beam (EOB), of 73.8 ± 2.1% (n = 3) and all yields correspond to a calculated saturation
yield of 134 ± 25MBq/μA. Natural Tl targets irradiated for 2 h at 8 or 9 μA produced,
on average as determined by gamma spectroscopy, 27.3 ± 4.7MBq (n = 5) and
32.9 ± 2.7MBq (n = 8) of 203Pb, respectively. Enriched 203Tl targets irradiated for 3.5 to
4 h at a current of 8 μA produced, as determined by gamma spectroscopy, 175.3MBq
and 201.9 MBq of 203Pb, respectively, corresponding to a calculated saturation yield of
Fig. 4 Separation of 228Th from other isotopes on a 1 × 8 Dowex anion exchange column (10 mL)
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483 ± 3MBq/μA (n = 2). The elution profile of an average 203Pb separation is shown in
Fig. 6.
Although both Pb products were observed to be radionuclidically pure, the elemental
purity was assessed via ICP-MS to quantify any stable impurities that may have inter-
fered with radiolabeling (Table 1). In the 203Pb product, moderate values of Tl were ob-
served with 58,220 ± 35,392 ppb (175 ± 105 μg; n = 3) present in the entire elute.
Although there was a ~ 1700 fold reduction in the mass of the Tl found in the elute
compared to the mass of the Tl present initially in the target, an additional washing
step may help to further reduce the mass found in the elute, which will be necessary
for clinical applications. Tl, Ca, Ge, Ni, and Zn were not found to be at levels above the
Fig. 5 Average elution profile for 228Th/212Pb separation from Pb resin using NH4OAc (1 M, pH 7) (n = 4)
Fig. 6 Average elution profile for 203Pb purification from Pb resin using NH4OAc (1 M, pH 7) (n = 6)
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blank concentration in the 212Pb product, while Th and Ti were not detected in the
203Pb product. Mg, Al, Ca, Fe, Co, Ni, Cu, Zn, and Pb were found in low to modest
amounts. Ca, Al, and stable Pb were of greatest concern as DOTA has a strong affinity
for Ca and Al (Clarke and Martell 1991), while stable Pb can compete with radioactive
Pb during the radiolabeling process as they are chemically identical and cannot be sepa-
rated. In the 212Pb product, the concentration of stable Pb was lower (2.1 ± 2.0 ppb;
6.4 ± 6.0 ng) than in the 203Pb product (495 ± 218 ppb; 1.49 ± 0.66 μg); however, Mg
and Ti concentrations were higher at 612 ± 226 ppb and 354 ± 168 ppb, respectively.
ICP-MS results for additional elements can be found in Table S1.
Radiolabeling studies
All radiolabeling reactions in this study were performed at room temperature and pH 7
in triplicate and the percent radiochemical yield (% RCY) is reported at the one-hour
time point as determined by radio-iTLC. The gold standard for Pb2+ complexation, p-
SCN-Bn-TCMC, had 203Pb-radiochemical yields of 97.2 ± 0.6%, 96.9 ± 0.6%,
43.7 ± 1.0%, and 3.7 ± 0.4% (n = 3), at concentrations of 10− 4 to 10− 7 M, respectively
(Fig. 6). When the study was repeated with 212Pb, the RCYs were 97.8 ± 0.4%,
98.1 ± 0.5%, 80.8 ± 8.9%, and 13.9 ± 1.6% (n = 3), respectively. DOTA, although not the
gold standard for Pb complexation but used in a number of 212Pb/203Pb preclinical
studies (Bartoś et al. 2013; Li et al. 2017; Garmestani et al. 2005; Miao et al. 2005; Jian-
quan et al. 2017; Miao et al. 2008), was able to efficiently complex 203Pb with radio-
chemical yields of 96.1 ± 1.0%, 75.8 ± 9.4%, 3.0 ± 0.8%, and 1.5 ± 0.2% at
concentrations of 10− 4 M to 10− 7 M, respectively. When the study was repeated with
212Pb, the RCYs were 97.6 ± 0.1%, 96.5 ± 0.8%, 4.3 ± 1.2%, and 3.6 ± 0.5%, respectively.
With 1–3 pyridine rings in place of the carboxylic acid groups found on DOTA, the
chelators DOTA-1Py, DOTA-2Py, and DOTA-3Py were able to efficiently complex
203Pb at the 10− 4 M concentration (RCYs of 97.0 ± 0.3, 97.6 ± 0.3%, and 97.7 ± 0.5%,
respectively). When repeated with 212Pb, all three of the chelators were able to complex
212Pb efficiently at not only 10− 4 M, but also at 10− 5 M. For both 203Pb and 212Pb, the
RCYs reduced sequentially at lower concentrations of 10− 5 to 10− 7 M. DOTA-1Py had
203Pb-RCYs of 80.6 ± 6.6%, 7.7 ± 5.0%, and 1.1 ± 0.2% at concentrations of 10− 5 to
10− 7 M, respectively, and when repeated with 212Pb over concentrations of 10− 4 to
10− 7 M, the RCYs were 97.0 ± 0.9%, 96.8 ± 0.6%, 13.0 ± 3.1%, and 4.6 ± 1.1%, respect-
ively. DOTA-2Py had 203Pb-RCYs of 87.6 ± 0.3%, 1.7 ± 0.6%, and 1.2 ± 0.3% at concen-
trations of 10− 5 to 10− 7 M, respectively. When repeated with 212Pb, at concentrations
of 10− 4 to 10− 7 M, the RCYs were 96.9 ± 0.8%, 97.4 ± 0.6%, 5.0 ± 0.4%, and 3.7 ± 0.8%,
respectively. DOTA-3Py had 203Pb-RCYs of 80.6 ± 6.6%, 27.2 ± 1.56%, and 1.7 ± 0.1%
at concentrations of 10− 5 to 10− 7 M, respectively. When repeated with 212Pb, with con-
centrations of 10− 4 to 10− 7 M, the RCYs were 97.6 ± 0.7%, 97.0 ± 0.1%, 26.9 ± 3.6%,
and 3.9 + 0.9%, respectively. The 212Pb and 203Pb radiolabeling results of these chela-
tors are shown in Fig. 7. Metal complexation with the chelators was also confirmed by
synthesizing non-radioactive Pb-complexes of all chelates and characterizing by mass
spectrometry and 1H NMR spectroscopy. The distinct isotope distribution pattern for
Pb (204Pb [1.4%], 216Pb [24.1%], 207Pb [22.1%], 208Pb [52.1%]) in the MS helped to con-
firm metal complexes (Figures S6, S7, S8, S9, S10).
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Human serum stability studies
The stability of 203Pb complexes in human serum for [203Pb][Pb(TCMC)]2+,
[203Pb][Pb(DOTA]2−, [203Pb][Pb(DOTA-1Py)]−, [203Pb][Pb(DOTA-2Py)],
[203Pb][Pb(DOTA-3Py)]+ is shown in Table 2. The radio-HPLC traces of the human
serum stability reactions are shown in Figure S14 in the supplementary data. All of the
commercial and pyridine-based chelators were exceptionally stable (> 95% stability at
72 h), as shown by both iTLC and radio-HPLC (Figure S15).
Discussion
203Pb and 212Pb produced at TRIUMF, either on the TR13 cyclotron or as a by-product
of 500MeV proton irradiation of 232Th, respectively, can be rapidly separated (< 3 h for
203Pb and < 1 h for 212Pb) with high radionuclidic purity (> 99%), moderate yield
(73.8 ± 2.1% for 203Pb, 69.3 ± 4.4% for 212Pb), and a chemical purity that is suitable for
pre-clinical screening of potential chelators to be used for theranostic purposes.
The direct elution of the Pb products into a radiolabeling compatible solution (1M
NH4OAc, pH 7) reduces the number of steps in the purification procedure and allows
for rapid, immediate use of the product for potential clinical purposes, an advantage
over methods that require the use of several columns or solution exchange, which can
prolong the radiochemist’s exposure to radiation. The use of a single Pb-selective ex-
traction resin allows for easy separation of 203Pb when the Tl target is dissolved in 2M
HNO3, Pb readily sorbs onto the resin while thallium passes through; thus there is no
need for solution exchange to produce a column compatible loading solution, reducing
the length of the procedure. In addition, when the nitric acid concentration is 2M the
capacity factor of Pb (k’Pb) is nearly 100 times greater than that of thallium (k’Tl) (Philip
Horwitz et al. 1994). Due to the high capacity factor of Pb on this resin, a single 60 mg
Fig. 7 Radiochemical yield (RCY, %) for a 212Pb and b 203Pb radiolabeling reactions at pH 7 and room
temperature at 1 h at chelator concentrations of 10− 4 – 10− 7 M




8 h 24 h 48 h 72 h
[203Pb][Pb(TCMC)]2+ 98.0 ± 0.5% 98.1 ± 0.2% 98.2 ± 0.3% 97.2 ± 0.7%
[203Pb][Pb(DOTA)]2− 97.1 ± 0.7% 97.3 ± 0.6% 98.1 ± 0.2% 97.4 ± 0.5%
[203Pb][Pb(DOTA-1Py)]− 97.4 ± 0.4% 97.7 ± 0.3% 98.1 ± 0.4% 97.5 ± 0.7%
[203Pb][Pb(DOTA-2Py)] 97.7 ± 0.1% 97.8 ± 0.1% 97.8 ± 0.9% 97.1 ± 0.2%
[203Pb][Pb(DOTA-3Py)]+ 98.4 ± 0.3% 98.0 ± 0.4% 98.4 ± 0.1% 97.7 ± 0.3%
Negative Control 1.2 ± 0.3% 1.4 ± 0.2% 1.4 ± 0.2% 1.5 ± 0.2%
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Pb resin column allowed for a 1700 fold reduction in Tl content, which is of import-
ance for clinical purposes due to the high toxicity of Tl. As shown in Table 1, in the en-
tire 3 mL elute 175 (+ 105) μg of thallium was found, and although the mass is below
regulated toxicity levels (occupational limit of 0.1 mg/m3 = approx. 6.5 mg of thallium
assuming an average body mass of 65 kg) (Kemnic and Coleman 2020), it would be
ideal to further reduce Tl content to reduce potential radiolabeling interference.
During method development, we found that increasing the column mass from 30 to
60mg reduced the percent of initial activity lost in the load from 40.3 + 1.0% to 20.5 +
0.5% (Figure S3). Further increasing the Pb-resin mass did not improve activity losses
in the load fraction. The volume of the loading solution was then optimised, and it was
found that reducing the loading volume from 30 to 20 mL reduced the loss of activity
in the load fraction from 20.5 + 0.5% to 8.7 + 0.3% (Figure S4). Other investigators have
loaded uncooled solutions onto columns (Li et al. 2017), however, in this study cooling
the solution to ambient temperature prior to loading the column was found to be crit-
ical, as it was found that the average yield of eluted 203Pb dropped to 36.1 + 9.6% at ele-
vated solution temperatures when compared to 73.8 + 2.1% cooled (Figure S5); we
hypothesize that the reduction in yield in the former was likely due to damage caused
to the resin’s structure upon exposure to the elevated temperature.
Previous animal studies have utilized approximately 6–7.5MBq of 203Pb-labeled bio-
conjugate for imaging studies (Miao et al. 2008; Yang et al. 2019). In human studies by
dos Santos and colleagues, 250–310MBq of 203Pb-labeled bioconjugate were required
for imaging and it was estimated that up to 750MBq could be utilized in future dosim-
etry studies (dos Santos et al. 2019). With 201.9 MBq of 203Pb produced by irradiating
enriched Tl at 8 μA for 4 h, it is reasonable to expect that with greater beam current
and longer irradiation times that sufficient quantities of 203Pb can be produced to en-
able both preclinical and clinical studies.
Despite the use of high purity (99.99% metals basis) thallium, significant levels of
stable Pb (1.49 + 0.66 μg) were found in the elute. At this level, experiments utilizing
lower amounts of activity will need to carefully consider the impact of molar activity
for radiolabeling and in vitro studies. Longer irradiation times and higher beam current
will produce more 203Pb and thus further decrease this ratio. Radiolabeling results
would be most improved if the source of the stable Pb was identified and the mass re-
duced. A potential source of stable Pb may be the thallium metal used for target manu-
facturing and future studies will evaluate different methods to increase molar activity.
Small (20 mCi) 224Ra generators are available, but their production is reliant on the
extraction of 228Th from an aging stockpile of 232U (Nuclear Science Advisory Commi-
tee : Isotopes Subcommmitee 2015). Due to the comparatively short half life of 224Ra
(t1/2 = 3.63 d), a
224Ra/212Pb generator can only be used for 1–2 weeks, thus increasing
costs of isotope production. 228Th/212Pb generators, however, could potentially be used
for extended periods of time. Herein we have reported the production and isolation of
228Th as a by-product of the proton irradiation of 232Th on TRIUMF’s 500MeV cyclo-
tron and is isolated by peroxide-induced precipitation (Robertson et al. 2020). Previous
generators used cation exchange columns and eluted 212Pb with water (Zucchini and
Friedman 1982), which is not immediately radiolabeling compatible, while others utilized
[228Th] barium stearate and collected 212Pb on glass walls (Hassfjell and Hoff 1994) and
with bubblers (Hassfjell 2001), and although these generators were effective, scaled-up
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production would be challenging, unlike the generator introduced in these studies. Al-
though there were radiochemical impurities in the final generator stock solution, as
shown in Fig. 4, with the high selectivity of the Pb resin employed in the generator, none
of these contaminants were observed in the elute fraction. The elute was also found to be
low in stable Pb (6 + 6 ng in 3mL), which resulted in higher radiolabeling yields, as ob-
served in Fig. 6, for all chelators, thus further demonstrating the potential of the pyridine-
based cyclen analogues (DOTA-xPy, x = 1–3) for chelation of Pb isotopes.
In previous animal studies, 0.2–7.4 MBq of 212Pb-labeled bioconjugates were used for
biodistribution and therapy studies (Miao et al. 2005; Stallons et al. 2019). In human
studies, dos Santos and colleagues predict the dose range for 212Pb-labeled bioconju-
gates to be 50 to 150MBq (dos Santos et al. 2019). Upon assembly, the generator pro-
duced 9.780 + 0.002MBq of 228Th and provided ~ 10MBq of 212Pb on elution, capable
of enabling both preclinical biodistribution and therapy studies. Although the current
activity produced is not high enough for clinical applications, further scale up efforts
are underway. The current purification procedure gives modest 212Pb yields of 69.3 +
4.4%, which may be due to the presence of approximately 8 g of 232Th present in the
generator stock solution hindering the sorption of 212Pb to the column. The ideal resin
mass used for the purification was 80mg, as opposed to 60 mg for 203Pb, as it was
found that larger masses did not increase the yield, but did increase the elute volume
required to reach the same yield. The mass of Th found in the elute (24,352 ± 16,227
ppb, 73.1 + 48.6 μg) represents a separation factor of approximately 105 (see Table 1).
Future work will examine process optimization that may further reduced Th burden.
All chelators showed quantitative RCYs (> 95%) at room temperature for both 203Pb
and 212Pb at a concentration of 10− 4 M. However, at 10− 5 M the 212Pb radiolabeling
yield was higher for all tested chelators and bioconjugates, demonstrating a positive ef-
fect of increased molar activity of the 212Pb compared to 203Pb. In order to avoid the
accumulation of stable 208Pb, the terminus of the 212Pb decay chain, the generator was
milked 24 h prior to radiolabeling tests and the next day’s elute was used for labeling
immediately in order to minimize the grow in of the stable daughter. In addition to the
commercial chelators, DOTA and p-SCN-Bn-TCMC, three pyridine-based cyclen li-
gands, DOTA-1Py, DOTA-2Py, and DOTA-3Py, were also screened for their ability to
complex 203Pb/212Pb, as the softer pyridine (N-) donors were hypothesized to form
stable metal-ligand coordinate bonds with the softer PbII ion (Price and Orvig 2014;
Ramogida and Orvig 2013). At 10− 5 M and ambient temperature, it was observed that
for the pyridine-based chelators, as the number of pyridine groups increased, so did the
radiolabeling yield; this trend was observed for both 212Pb and 203Pb. With the greatest
radiolabeling yield of the pyridine-based chelators and with high human serum stability
(> 97% at 72 h), DOTA-3Py shows the greatest promise as a new Pb chelator and is a
good candidate for incorporation into a bioconjugate for theranostic purposes.
Conclusion
Routine production of both members of the 212Pb/203Pb theranostic pair was estab-
lished at TRIUMF. 228Th, a by-product of 232Th spallation on TRIUMF’s 500MeV
cyclotron, was used to produce a novel 228Th/212Pb generator and was combined with
203Pb production via thallium irradiation with 13MeV protons. Both 203Pb and 212Pb
were produced at quantities and purities (radionuclidic and chemical) acceptable for
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preclinical radiopharmaceutical screening. Increased irradiation times may lead to pro-
duction at clinical quantities. Separation of the lead products was achieved using a Pb-
selective extraction chromatographic resin in moderate yields (73.8 + 2.1% for 203Pb,
69.3 + 4.4% for 212Pb) in a form suitable for direct radiolabeling. The lead products
were used to screen the radiolabeling ability and serum stability with commercially
available (DOTA and p-SCN-Bn-TCMC) and pyridine-based DOTA derivative chela-
tors (DOTA-1Py, DOTA-2Py, and DOTA-3Py). DOTA-1Py, −2Py, and -3Py all exhib-
ited ability to complex 212Pb/203Pb at ambient temperature, with [212Pb/203Pb]Pb-
DOTA-3Py showing the highest radiolabeling yield of the three. Further investigation
of the PbII-coordination chemistry with these ligands as well as preparation of biocon-
jugates for in vivo studies are planned in the future. In conclusion, together these stud-
ies demonstrate the ability of TRIUMF to produce a theranostic pair that can be used
for pre-screening potential radiopharmaceuticals at the pre-clinical level with the po-
tential to increase production to the clinical level.
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